

All sponsors have provided sponsorship towards this independent programme. Sponsors have had no input into the content of the programme or the choice of speakers and have provided sponsorship monies used towards the meeting costs. Sponsors will have the opportunity to exhibit with a company stand during the meeting.

#### Premium Sponsors

 Binding Site



**sanofi**



**Stemline**  
A Menarini Group Company

**Johnson & Johnson**  
Innovative Medicine

#### Standard Sponsors



**AMGEN**

 Bristol Myers Squibb

**AstraZeneca**

**sebia**  
The new language of life



## UK Myeloma Society Autumn Day Incorporating Latest Developments into Clinical Practice – Diagnostics, Novel Therapies and MDT Dilemmas

**Wednesday 11<sup>th</sup> November 2026**

**Hybrid Event from the Cavendish Conference Centre, 22 Duchess Mews, London W1G 9DT**

*Register to attend in person or watch a live stream*

**Joint Chairs: Dr Jaimal Kothari** (Oxford University Hospitals)  
**Dr Sarah Lawless** (Belfast City Hospital)

09.00 *Registration, coffee & exhibition*

09.25 Welcome and introduction

09.30 UK practice and access updates

**Dr Ceri Bygrave**  
*University Hospital of Wales*

09.50 College of Myeloma UK - reflections on career and advocacy role

**Dr Neil Rabin**  
*University College London Hospitals*

10.00 College of Myeloma UK - reflections on career and advocacy role

**Professor Hermann Einsele**  
*University Hospital Würzburg*

10.10 Best of IMS 2026 - Glasgow

**Dr Jennifer Travers**  
*Beatson West of Scotland Cancer Centre  
Glasgow*

10.30 *Coffee & exhibition*

11.00 **IMS Abstracts and EHA Abstracts**

Exploring the epigenetic role of PRDM1: a target for IMiD-resistant multiple myeloma

**Sophie Ball**  
*Imperial College Healthcare*

Ambulatory delivery of bispecific antibodies in relapsed multiple myeloma (RRMM) via a virtual ward pathway: reduced inpatient bed-days and preserved safety

**Veronica Lewis**  
*Addenbrooke's Hospital, Cambridge*

IMS x 2

#### **Michael Morley Lecture**

11.30 New developments in first line therapy

**Dr Francesca Gay**  
*University of Turin*

12.20 *Lunch, networking & exhibition*

13.20 *AGM*

## Parallel Sessions: Clinical and Scientific

### UKMRA Science Forum

*In person attendance only. See next page for more information.*

- 13.30 Speakers  
14.30 Coffee break  
15.00 Speakers  
15.30 Networking and collaboration session  
16.00 Summary and close

*If you wish to attend this session, please ensure that you select the appropriate package when completing your registration. Places are limited.*

### PORTLAND ROOM

### State of the Art Diagnostics

- 13.30 Identifying high risk patients

**Dr Kevin Boyd**  
*The Royal Marsden*

- 13.50 Imaging role of WBMRI

**Dr Gordon Cowell**  
*Queen Elizabeth University Hospital,  
Glasgow*

- 14.10 The pros and cons of Pet/CT in multiple myeloma

**Dr Shaheel Bhuva**  
*Imperial College Healthcare*

- 14.30 *Coffee break*

### Sequencing Dilemmas

- 15.00 Sequencing immunotherapies

**Professor Hermann Einsele**  
*University Hospital Würzburg*

Case 1: Choosing bispecific antibodies

Case 2: Managing patients post bispecifics/post BCMA

Case 3: Primary refractory/progression on DVRd

- 16.00 *Close*

### Registration:

Standard Fee (until 28 October)  
£80 (£55 for Scientists, Nurses & Pharmacists)

Late Fee (from 29 October)  
£135 (£90 for Scientists, Nurses & Pharmacists)

**Registration now open at [www.collaborativeconferences.co.uk/ukmsociety](http://www.collaborativeconferences.co.uk/ukmsociety)**

*Online registration for this meeting is for healthcare professionals only  
Please indicate if you wish to attend in person or watch the live stream while completing the registration form*

**Enquiries: Please contact Alex - [alex@collaborativeconferences.co.uk](mailto:alex@collaborativeconferences.co.uk)**

*The UK Myeloma Society exists to improve the care of myeloma patients through education and the promotion of trials*

### Premium Sponsors



**sanofi**



**Johnson & Johnson  
Innovative Medicine**

### Standard Sponsors



*All sponsors have provided sponsorship towards this independent programme. Sponsors have had no input into the content of the programme or the choice of speakers and have provided sponsorship monies used towards the meeting costs. Sponsors will have the opportunity to exhibit with a company stand during the meeting.*

## UKMRA Science Forum at the UK Myeloma Society Autumn Day

Wednesday 11<sup>th</sup> November 2026

Cavendish Conference Centre - PORTLAND ROOM

### Leading the Session:

**Dr Shelly Lawson** (Sheffield)

**Dr Sarah Gooding** (Oxford)

13.30	Pre-clinical evaluation of the CBP/p300 degrader CBPD-409 in multiple myeloma	<b>Dr Mark Williams</b> <i>Glasgow Caledonian University</i>
13.45	Pre-clinical evaluation of a dual action strategy to enhance myeloma therapy and prevent peripheral neuropathy	<b>Dr Lisa Crawford</b> <i>Queen's University Belfast</i>
14.00	BCMA-targeted MMAF therapy for multiple myeloma	<b>Dr Zahraa Al-Amady</b> <i>University of Sheffield</i>
14.15	Targeting Cks1b in myeloma	<b>Dr Claire Seedhouse</b> <i>University of Nottingham</i>
14.30	<i>Coffee break</i>	
15.00	Investigation of therapeutic vulnerabilities in high-risk myeloma and extramedullary disease	<b>Prof Siobhan Glavey</b> <i>Beaumont Hospital, Dublin</i>
15.15	Genome-scale maps of progression signatures for individual myeloma patients and candidate synthetic lethal vulnerabilities to overcome drug resistance	<b>Dr Ian Overton</b> <i>Queen's University Belfast</i>
15.30	Networking / collaboration session (speed networking)	
16.00	Summary and close	

### Premium Sponsors



**sanofi**



**Johnson & Johnson**  
Innovative Medicine

### Standard Sponsors



*All sponsors have provided sponsorship towards this independent programme. Sponsors have had no input into the content of the programme or the choice of speakers and have provided sponsorship monies used towards the meeting costs. Sponsors will have the opportunity to exhibit with a company stand during the meeting.*